While IL-6 serum levels are higher in patients with arthritis, this cytokine has also been associated with severe systemic manifestations such as macrophage activation syndrome [17], and therapeutic blockade of IL-6 provided excellent clinical responses in SJIA patients with systemic phenotype [22]. Here, IL6 is linked to macrophage activation syndrome.